This company listing is no longer active
Calliditas Therapeutics Valuation
Is CALTXS undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of CALTXS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: CALTXS (SEK207.4) is trading below our estimate of fair value (SEK10362.05)
Significantly Below Fair Value: CALTXS is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for CALTXS?
Key metric: As CALTXS is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is CALTXS's PS Ratio? | |
|---|---|
| PS Ratio | 7x |
| Sales | SEK 1.60b |
| Market Cap | SEK 11.18b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 7.1x |
| Enterprise Value/EBITDA | -31.2x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does CALTXS's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 3.3x | ||
INDV Indivior | 1.1x | 5.5% | UK£1.1b |
HCM HUTCHMED (China) | 4.8x | 18.0% | UK£2.4b |
APH Alliance Pharma | 1.3x | 5.2% | UK£243.5m |
DPH Dechra Pharmaceuticals | 5.8x | 7.9% | UK£4.4b |
CALTXS Calliditas Therapeutics | 7x | 34.3% | SEK 11.2b |
Price-To-Sales vs Peers: CALTXS is expensive based on its Price-To-Sales Ratio (7x) compared to the peer average (3.3x).
Price to Sales Ratio vs Industry
How does CALTXS's PS Ratio compare vs other companies in the GB Pharmaceuticals Industry?
| 1 Company | Price / Sales | Estimated Growth | Market Cap |
|---|---|---|---|
EAH ECO Animal Health Group | 0.5x | 5.9% | US$55.67m |
| 1 Company | Estimated Growth | Market Cap |
|---|
Price-To-Sales vs Industry: CALTXS is expensive based on its Price-To-Sales Ratio (7x) compared to the European Pharmaceuticals industry average (4.3x).
Price to Sales Ratio vs Fair Ratio
What is CALTXS's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 7x |
| Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate CALTXS's Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
hVIVO
UK£134.7m
Operates as a pharmaceutical service and contract research company in the United Kingdom.
HVO
UK£0.20
7D
-16.8%
1Y
2.1%
Formycon
€844.9m
A biotechnology company, develops biosimilar drugs in Germany and Switzerland.
0W4N
€48.35
7D
2.8%
1Y
-24.9%
Regeneron Pharmaceuticals
US$81.0b
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.
0R2M
US$749.80
7D
1.3%
1Y
-7.7%